June 2026 President’s Letter

Dear Colleagues,

Welcome to my PES monthly President's Newsletters! I want to begin by expressing my heartfelt gratitude to Dr. Laurie Cohen for her outstanding leadership this past year. She is a role model for us all. I am deeply honored to step into this role and to work alongside our members in advancing PES's mission: "to advance and promote the endocrine health of children, adolescents and young adults and support the professionals that work on their behalf."

June always carries a special energy with warmer days, a sense of culmination, and the bittersweet joy of watching our trainees move forward. To our graduating fellows: congratulations, you did it! After four years of college, four years of medical school, three years of residency, and three years of fellowship, you have earned every bit of this moment. Please take time to reflect on how far you've come, not just in clinical knowledge and professional skills, but as people. You and your families deserve to celebrate wholeheartedly.

I still vividly remember my first day as an attending. After the intern presented the patient on rounds, the case manager looked directly at me and asked, "So, the patient is ready for discharge?" There was no one behind me, no one to call. The decision was mine. That was the moment I understood that the responsibility to advocate for the best care now rested with me. What makes this decision less daunting is that in pediatric endocrinology we never make these decisions alone. We lean on each other: our colleagues, trainees, nurses, CDEs, and staff, working together in advocating for our patients.

And this month, that collective voice matters more than ever. As a professional society of physicians, advanced practice providers, educators, and researchers, we must advocate not only for excellent clinical care, but for the preservation of pediatric research and the therapies our patients depend on. Our years of training give us the expertise to know what is best for our patients and their families and our shared commitment to improve that care. We cannot allow those without medical training to defund our studies, obstruct our innovation, or restrict lifesaving therapies. I encourage every member to submit comments on the proposed Regulations for Federal Financial Assistance by July 13, 2026. All children, adolescents, and young adults deserve quality healthcare, and we must be their voice.

Until next month, I hope you find time to enjoy the warm days ahead; you've earned them too.

Warmly,

Tandy Aye, MD
President, PES Board of Directors

2026 Annual Meeting Content - Coming Soon!

2026 Annual Meeting attendees will soon receive an email with access to available session recordings and presentation slides. Resources will include only those sessions for which presenters granted permission to record and share their content. Keep an eye on your inbox!

2027 Annual Meeting: Call for Session Proposals

Have an idea for an engaging session or an important topic to feature at the 2027 PES Annual Meeting?

The Program Committee invites all members to submit proposals and speaker recommendations for Scientific Symposia, Workshops, Meet-the-Professor sessions, and Spark Sessions for next year's Annual Meeting in Minneapolis, Minnesota.

Our members bring invaluable expertise and fresh perspectives, and your ideas help shape a meeting that is relevant, innovative, and impactful. Whether you have a fully developed concept or a timely topic you'd like to see included, we encourage you to share your suggestions.

Please submit your proposal using the link below by Friday, July 31. All submissions received by the deadline will be carefully reviewed by the Program Committee.

Don't miss this opportunity to help shape the educational program for the 2027 Annual Meeting!

Submit your idea

New Meds and Tech from the D&T Committee

Afrezza: Rapid-Acting Inhaled Insulin Approved for Children ≥ 6 Years Old with Diabetes

Prepared on behalf of PES Drugs and Therapeutics Committee by Pranav Gupta, MD and edited by Dania Al-Hamad, MD and Neha Patel, DO

Afrezza® (insulin human) inhalation powder is a drug and device combination product consisting of a rapid-acting Technosphere® insulin (TI) and an oral inhaler device (the Gen2 inhaler) that was initially approved in the US to improve glycemic control in adults with diabetes in June 2014. It is currently the only inhaled insulin approved and marketed in the USA. 1 Read more

Teplizumab Approval Expanded to Stage 3 Type 1 Diabetes (Ages 8-17)

Prepared on behalf of PES Drugs and Therapeutics Committee by Neha Patel, DO

Teplizumab (Tzield™), a humanized anti–CD3 monoclonal antibody, is a disease-modifying therapy targeting the autoimmune process in type 1 diabetes (T1D). It was initially approved by the FDA in November 2022 for individuals ≥8 years of age with stage 2 T1D,1 and now has received accelerated approval for use in stage 3 T1D in patients aged 8–17 years. 2-3 Read more

IMCIVREE® (setmelanotide) injection

Prepared by Daniel Mak, MD; Edited by Neha Patel, DO

On March 19, 2026, the FDA approved and expanded indication for IMCIVREE® (setmelanotide), establishing it as the first and only FDA-approved therapy for patients aged 4 years and older with acquired hypothalamic obesity (aHO).1

The FDA approval was supported by data from the global Phase 3 TRANSCEND trial, which evaluated 142 patients with aHO over a 52-week period. Among enrolled participants, 47% were adults, 31% were aged 12 to <18 years, and 23% were 4 to <12 years. 1, 2 Read more

Drugs and Therapeutics Shortage Update: Estradiol Transdermal Patch

Prepared by Daniel Mak, MD; Edited by Neha Patel, DO

On 3/12/26, the American Society of Health-System Pharmacists (ASHP) reported shortages of estradiol transdermal patches from multiple manufacturers, including Amneal, Noven, Sandoz, and Zydus.1 Although specific products were not listed, media reports note limited availability of major brands such as Vivelle-Dot® and Climara®. Estimated resupply dates range from mid-March (Zydus) to mid-April (Sandoz), while other manufacturers have not provided timelines. 1 Read more

Rising Star Grant Applications Now Open

Now Accepting 2026 PES Rising Star Grant and The Raphael David, MD Rising Star Grant Applications!

Application Deadline: September 15 @ 5:00 PM Eastern

Funding Start Date: November 1

The purpose of these small grants is to support and encourage research efforts of pediatric endocrinology fellows.

PES funds 5 Rising Star Grants (RSGs) per year. One of these awards is a named RSG (The Raphael David, MD Rising Star Grant) that will be given preferentially to an application related to the developmental biology of the testes or adrenal gland. The RSG program is in addition to the already established and larger Research Fellowship Grant (RFG) program.

Click below for more information and to apply:

PES Rising Star Grant - Pediatric Endocrine Society

The Raphael David, MD Rising Star Grant - Pediatric Endocrine Society

Now Accepting Nominations for 2026 Laureate Awards & Lectures

Deadline: October 9 @ 5:00 PM Eastern

Laureate Awards:

Judson J. Van Wyk Prize
New Investigator Award
Clinician Award
Educator Award
Mid-Career Investigator Award
Outstanding PES Mentor Award

Lectures:

The Robert M. Blizzard, MD Lectureship (offered odd years)
Paul Kaplowitz, MD Endowed Lectureship

Please note that all nominations must be submitted through the online application available on each award and lecture page. Before beginning the application, please review the required nomination materials to ensure you have all necessary information and documents.

For more information and nomination applications: Awards, Grants & Lectureships - Pediatric Endocrine Society

New Guideline Now Available: Central Precocious Puberty: An Endocrine Society Clinical Practice Guideline

We are very excited to share that the guideline “Central Precocious Puberty: An Endocrine Society Clinical Practice Guideline” is now published online at: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgag168/8697368?searchresult=1

The accompanying systematic review titled “A Systematic Review Supporting the Clinical Practice Guidelines on Central Precocious Puberty” is also published at: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgag169/8697369?searchresult=1

In addition to the guideline, panel members have been working on derivative products for patients, clinicians, and stakeholders. These resources can be found on the guideline resource page here: https://www.endocrine.org/clinical-practice-guidelines/central-precocious-puberty.

Thanks to Dr. Erica Eugster for serving as the official PES representative. Her contributions were invaluable in the development of this guideline.

Online Education

PES takes pride in providing diverse online educational opportunities for our members. Our offerings include the PES SIG State of the Art Series webinars, the Quarterly Education Committee-sponsored webinar series, and the Industry Sponsored Symposia Series, all available year-round. These educational resources are among the exclusive benefits of PES membership.

Check out our education calendar for more details and links to register/access: Events for July 2026 – Pediatric Endocrine Society

SAVE THE DATE

July 20 I 4:00 - 5:00 PM Eastern

Quarterly Education Webinar: Collateral Damage: Radiation’s Effect on Endocrine Organs

Wednesday, July 15 I 7:00 PM Eastern

Industry Sponsored Symposium: Shifting The T1D Paradigm: Early Detection, Disease Modification, and Beta-Cell Preservation

With the advent of disease-modifying therapies to delay progression of type 1 diabetes (T1D), as well as their potential application of these therapies in newly diagnosed T1D, there is an increased emphasis on presymptomatic screening, staging, and monitoring—representing a true paradigm shift in how we address the disease. This proactive approach is paramount in pediatric populations, who are at higher risk for progression after testing positive for islet autoantibodies. This symposium will provide an overview of the practical considerations for early detection of T1D and the application of disease-modifying therapy for delaying disease progression in pediatric patients, while also exploring emerging treatment approaches aimed at preserving beta cell function in newly diagnosed T1D.

Speakers:

Daniel DeSalvo, MD, Associate Professor, Pediatric Diabetes & Endocrinology, Baylor College of Medicine, Texas Children's Hospital, Director of Strategic Collaboration, Texas Children's Diabetes Care Center, Houston, Texas

Roshanak Monzavi, MD, Clinical Professor of Pediatrics, Director of Fellowship Program, Center for Endocrinology, Diabetes, and Metabolism, Children’s Hospital Los Angeles, Los Angeles, California

Learning objectives:

Implement risk-based screening approaches to facilitate timely identification of presymptomatic T1D
Analyze T1D screening results to determine disease stage and inform appropriate monitoring and referral decisions
Develop individualized treatment strategies that incorporate disease-modifying therapies to delay T1D progression in eligible patients
Recognize the importance of beta-cell preservation on T1D prognosis and outcomes
Review emerging approaches aimed at beta cell preservation & their potential future application in new-onset T1D

CME: 1.0 Credits

Registration link: https://www.medlearninggroup.com/cme-programming/db-pes-vs/

This activity is provided by Med Learning Group and supported by an educational grant from Sanofi US.

Advocacy Spotlight: Call to Action - Regulation for Federal Financial Assistance

The Office of Management and Budget (OMB) has released a proposed rule, Federal Register: Regulation for Federal Financial Assistance, that would make broad changes to the regulations governing federal grants and other forms of federal funding. The proposal includes provisions that may affect pediatric endocrine research, training programs, and academic medical centers, including policies related to award selection, suspension and termination of awards, nondiscrimination requirements, and other administrative requirements for federal funding recipients.

The Research Affairs Committee has reviewed the proposal and submitted comments on behalf of PES. We encourage members to review the proposed rule Federal Register: Regulation for Federal Financial Assistance, and, if interested, submit comments based on their own expertise and experience. Comments are due July 13, 2026.

SUMMARY LINK

COMMENTS LINK